Cell death in pancreatic cancer: from pathogenesis to therapy

X Chen, HJ Zeh, R Kang, G Kroemer… - Nature reviews …, 2021 - nature.com
Pancreatic cancer is a devastating gastrointestinal cancer characterized by late diagnosis,
limited treatment success and dismal prognosis. Exocrine tumours account for 95% of …

The role of p53 in cancer drug resistance and targeted chemotherapy

K Hientz, A Mohr, D Bhakta-Guha, T Efferth - Oncotarget, 2016 - pmc.ncbi.nlm.nih.gov
Cancer has long been a grievous disease complicated by innumerable players aggravating
its cure. Many clinical studies demonstrated the prognostic relevance of the tumor …

Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches

E Alvarado-Ortiz, KG de la Cruz-López… - Frontiers in cell and …, 2021 - frontiersin.org
Frequent p53 mutations (mutp53) not only abolish tumor suppressor capacities but confer
various gain-of-function (GOF) activities that impacts molecules and pathways now regarded …

Clinical overview of MDM2/X-targeted therapies

A Burgess, KM Chia, S Haupt, D Thomas… - Frontiers in …, 2016 - frontiersin.org
MDM2 and MDMX are the primary negative regulators of p53, which under normal
conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid …

Molecular and cellular paradigms of multidrug resistance in cancer

FU Vaidya, A Sufiyan Chhipa, V Mishra… - Cancer …, 2022 - Wiley Online Library
Background The acquisition of resistance to chemotherapy is a major hurdle in the
successful application of cancer therapy. Several anticancer approaches, including …

New therapeutic strategies to treat human cancers expressing mutant p53 proteins

G Blandino, S Di Agostino - Journal of Experimental & Clinical Cancer …, 2018 - Springer
The tumor suppressor p53 plays a critical role to preserve DNA fidelity from diverse insults
through the regulation of cell-cycle checkpoints, DNA repair, senescence and apoptosis …

Small-molecule MMRi62 induces ferroptosis and inhibits metastasis in pancreatic cancer via degradation of ferritin heavy chain and mutant p53

J Li, R Lama, SL Galster, JR Inigo, J Wu… - Molecular cancer …, 2022 - AACR
High frequency of KRAS and TP53 mutations is a unique genetic feature of pancreatic ductal
adenocarcinoma (PDAC). TP53 mutation not only renders PDAC resistance to …

Pro-survival autophagy and cancer cell resistance to therapy

CK Das, M Mandal, D Kögel - Cancer and Metastasis Reviews, 2018 - Springer
Resistance to therapy is one of the prime causes for treatment failure in cancer and recurrent
disease. In recent years, autophagy has emerged as an important cell survival mechanism …

[HTML][HTML] Ten hub genes associated with progression and prognosis of pancreatic carcinoma identified by co-expression analysis

Z Zhou, Y Cheng, Y Jiang, S Liu, M Zhang… - … journal of biological …, 2018 - ncbi.nlm.nih.gov
Since the five-year survival rate is less than 5%, pancreatic ductal adenocarcinoma (PDAC)
remains the 4th cause of cancer-related death. Although PDAC has been repeatedly …

Cancer stemness: p53 at the wheel

D Ghatak, D Das Ghosh, S Roychoudhury - Frontiers in oncology, 2021 - frontiersin.org
The tumor suppressor p53 maintains an equilibrium between self-renewal and
differentiation to sustain a limited repertoire of stem cells for proper development and …